NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHGRI E-018-1997-0-EP-06 AIB1, A NOVEL STEROID RECEPTOR CO-ACTIVATOR AMPLIFIED IN BREAST CANCER EP National Stage 98931358.0 Abandoned
NHGRI E-018-1997-0-AU-04 AIB1, A NOVEL STEROID RECEPTOR CO-ACTIVATOR AMPLIFIED IN BREAST CANCER AU National Stage 81506/98 Abandoned
NHGRI E-018-1997-0-PCT-02 AIB1, A NOVEL STEROID RECEPTOR CO-ACTIVATOR PCT PCT PCT/US1998/012689 Expired
NHGRI E-018-1997-0-JP-07 AIB1, A NOVEL STEROID RECEPTOR CO-ACTIVATOR AMPLIFIED IN BREAST CANCER JP National Stage 1999-504793 Abandoned
NCI E-025-1998-0-US-01 FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS US 60/089,619 Abandoned
NCI E-051-1995-1-US-01 Compositions and Methodsfor Modulatin Proteolytic Degradation of Intracellular Targets. US CIP 09/096,889 Abandoned
NCI E-201-1998-0-US-01 SPECIFIC KILLING OF HIV-INFECTED LYMPHOCYTES BY A RECOMBINANT IMMUNOTOXIN DIRECTED AGAINST THE HIV-1 GP 120 ENVELOPE GLYCOPROTEIN US 60/088,860 Abandoned
NINDS E-049-1996-0-US-03 MUTANT FORM OF AN CYTOTOXIC RIBONUCLEOLYTIC PROTEIN WHICH ALLOWS PRODUCTION BY RECOMBINANT METHODS US DIV 09/095,429 6649393 Abandoned PDF
NCI E-008-1998-0-US-01 B2 Microglobulin Fusion Proteins and High Affinity Variants US 60/088,813 Abandoned
NCI E-148-2007-2-US-10 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses US DIV 09/092,077 6194142 Expired PDF
CC E-180-1998-0-US-01 REAL-TIME INTERACTIVE FUNCTIONAL MAGNETIC RESONANCE IMAGING US ORD 09/090,166 Abandoned
NIDDK E-005-1998-0-AU-03 METHODS AND COMPOSITIONS FOR PROTECTING AGAINST CARDIAC ISCHEMIA BY ADMINISTERING ADENOSINE A2A RECEPTOR ANTAGONISTS AU National Stage 63462/98 Abandoned
NIDDK E-005-1998-0-EP-05 METHODS AND COMPOSITIONS FOR PROTECTING AGAINST CARDIAC ISCHEMIA BY ADMINISTERING ADENOSINE A2A RECEPTOR ANTAGONISTS EP National Stage 98907720.1 Abandoned
NCI E-160-1997-2-US-01 Polynucleotides Encoding Human FRP and Fragments Thereof US CIP 09/087,031 6479255 Expired PDF
NCI E-160-1997-3-PCT-01 HUMAN FRP AND FRAGEMTS THEREOF INCLUDING METHODS FOR USING THEM PCT PCT COMB PCT/US1998/010974 Expired
NCI E-008-1996-0-US-04 C-C CHEMOKINES THAT INHIBIT RETROVIRUS INFECTION US National Stage 09/077,614 Abandoned
NHGRI E-236-1999-0-US-01 Methods and Compositions Useful of Modulation of Angiogenesis Using Tyrosine Kinase SRC US 60/087,220 Abandoned
NIMH E-162-1998-0-US-01 MAMMALIAN GB2 GABAB RECEPTORS US 60/087,274 Abandoned
NICHD E-225-1997-0-PCT-02 USE OF RECOMBINANT HUMAN UTEROGLOBIN IN TREATMENT OF INFLAMMATORY AND FIBROTIC CONDITIONS PCT PCT PCT/US1998/011026 Expired
NHLBI E-196-1998-1-US-01 Pressure Mediated Selective Delivery of Therapeutic Substances US 60/087,099 Abandoned
NHLBI E-127-1998-0-US-01 AAV5 AND USES THEREOF US 60/087,029 Abandoned
NCI E-167-1997-0-JP-05 The Use of A Nitroxide or a Prodrug Thereof in the Prophylactic and Therapeutic Treatment of Cancer JP National Stage 1999-500817 Abandoned
NCI E-167-1997-0-CA-04 THE USE OF A NITROXIDE OR A PRODRUG THEREOF IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF CANCER CA National Stage 2289017 Abandoned
NCI E-167-1997-0-DE-12 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects DE EP 98923772.2 Abandoned
NCI E-167-1997-0-FR-11 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects FR EP 98923772.2 Abandoned
NCI E-167-1997-0-DK-10 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects DK EP 98923772.2 Abandoned
NCI E-167-1997-0-BE-09 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects BE EP 98923772.2 Abandoned
NCI E-167-1997-0-AT-08 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects= AT EP 98923772.2 Abandoned
NCI E-167-1997-0-LU-16 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects LU EP 98923772.2 Abandoned
NCI E-167-1997-0-CH-22 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects CH EP 98923772.2 Abandoned
NCI E-167-1997-0-SE-21 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects SE EP 98923772.2 Abandoned
NCI E-167-1997-0-GB-23 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects GB EP 98923772.2 Abandoned
NCI E-167-1997-0-MC-17 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects MC EP 98923772.2 Abandoned
NCI E-167-1997-0-NL-18 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects NL EP 98923772.2 Abandoned
NCI E-167-1997-0-ES-20 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects ES EP 98923772.2 Abandoned
NCI E-167-1997-0-PT-19 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects PT EP 98923772.2 Abandoned
NCI E-167-1997-0-IE-14 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects IE EP 98923772.2 Abandoned
NCI E-167-1997-0-GR-13 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects GR EP 98923772.2 Abandoned
NCI E-167-1997-0-IT-15 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects IT EP 98923772.2 Abandoned
NCI E-167-1997-0-EP-06 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects EP National Stage 98923772.2 Abandoned
NCI E-167-1997-0-AU-03 The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer due to Genetic Defects AU National Stage 75987/98 Abandoned
NCI E-167-1997-0-PCT-02 The Use of a Nitroxide and a Prodrug Thereof in the Prophylactic and Therapeutic Treatment of Cancer PCT PCT PCT/US1998/010685 Expired
NIAID E-032-1994-0-US-02 NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF HEPATITIS C VIRUS AND USE OF REAGENTS DERIVED FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND VACCINES US DIV 09/084,691 7070790 Abandoned PDF
CC E-142-1998-0-US-01 Labeling DNA Plasmids with Triplex-Forming Oligonucleotides, and Methods for Assaying Distribution of DNA Plasimids in Vivo US 60/086,704 Abandoned
NIAID E-089-1997-2-BR-03 PRODUCTION OF PARAINFLUENZA VIRUS FROM CLONED NUCLEOTIDE SEQUENCES BR National Stage PI9809456-4 Abandoned
NIAID E-089-1997-2-IT-20 PRODUCTION OF ATTENUATED PARAINFLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES IT EP 98926055.9 Abandoned
NIAID E-089-1997-2-DE-16 PRODUCTION OF ATTENUATED PARAINFLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES DE EP 98926055.9 Abandoned
NIAID E-089-1997-2-FR-18 PRODUCTION OF ATTENUATED PARAINFLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES FR EP 98926055.9 Abandoned
NIAID E-089-1997-2-ES-17 PRODUCTION OF ATTENUATED PARAINFLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES ES EP 98926055.9 Abandoned
NIAID E-089-1997-2-CH-15 PRODUCTION OF ATTENUATED PARAINFLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES CH EP 98926055.9 Abandoned